Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Alparis S A De C V has 1 pending office action in Biotechnology & Pharmaceuticals. This action involves 1 distinct examiner and 1 distinct art unit. The current prosecution landscape is singular, with all activity focused on one specific application. This suggests a streamlined approach where the company is currently focused on a specific technical advancement rather than a broad array of filings.
PALENIK, JEFFREY T is the busiest examiner, managing the 1 pending office action. Because there is only 1 distinct examiner and 1 distinct art unit, the interaction with the USPTO is highly direct. Practitioners can tailor their responses specifically to the expectations of this single examiner. This centralized examination structure allows for a more predictable interaction with the patent office, as there are no competing examiner styles or differing art unit standards to navigate for the current pending matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PALENIK, JEFFREY T | 1 | 53.5% | +27.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18516509 | CO-AMORPHOUS SOLID FORMS OF FLAVONOIDS | PALENIK, JEFFREY T | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18516509 | CO-AMORPHOUS SOLID FORMS OF FLAVONOIDS | PALENIK, JEFFREY T | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18516509 | CO-AMORPHOUS SOLID FORMS OF FLAVONOIDS | PALENIK, JEFFREY T | 1615 | §102§103 | Non-Final OA | — | Pending | Nov 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlparis S A De C V has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jeffrey T Palenik has the most, with 1 of Alparis S A De C V's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
